| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S89195-5mg促销 |
≥97% | ￥1540.00 ￥1380.00 |
2 | - | - | - | - |
|
S89195-10mg促销 |
≥97% | ￥2700.00 ￥2430.00 |
4 | - | - | - | - |
|
S89195-25mg促销 |
≥97% | ￥4600.00 ￥4140.00 |
3 | - | - | - | - |
|
S89195-50mg促销 |
≥97% | ￥6600.00 ￥5940.00 |
3 | - | - | - | - |
|
S89195-100mg促销 |
≥97% | ￥9000.00 ￥8100.00 |
2 | - | - | - | - |
|
| 产品描述： | Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | Menin-MLL;EpigeneticReaderDomain; HistoneMethyltransferase | ||||||||||||||||||||
| 体内研究： | Revumenib (SNDX-5613) shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts | ||||||||||||||||||||
| 参考文献： | 1. A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory). | ||||||||||||||||||||
| 溶解性： | Soluble in DMSO | ||||||||||||||||||||
| 保存条件： | -20°C | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京